Gerard J. Criner, MD, FACP, FACCP, Chair and Professor of Thoracic Medicine and Surgery at the Lewis Katz School of Medicine at Temple University and Director of the Temple Lung Center, and the Lung Center team treated the first two U.S. patients as part of the AIRFLOW-3 international clinical trial. The patients received targeted lung denervation therapy, a one-time bronchoscopic procedure that disrupts pulmonary nerve input to the lung. The study will evaluate targeted lung denervation in addition to medical care to reduce moderate to severe COPD exacerbations and related hospitalizations compared with optimal medical care alone. Markets Insider, Marketplace, The Pittsburgh Post-Gazette, Yahoo! Finance, The Arizona Republic, and other outlets covered the achievement.